Understanding Biological Risk

- Extraordinary advances in life sciences and biotechnology bring enormous benefits to medicine, public health, and agriculture

- But the risk to public safety and security from the misuse of this science and technology needs to be minimized by the engagement of the life sciences community
Spectrum of Biological Risk

- Naturally occurring disease
- Re-emerging disease
- Anti-biotic resistant disease
- Accident or misadventure
- Deliberate use – state or non-state

Pace of the Advances

- Moore’s Law – computing power doubles every 18 months
- Carlson’s Law
  - Starting in 2002 it took two years for a team to synthesize the polio virus
  - In 2005 it took two weeks for a team to synthesize a virus of comparable length
- Cost reducing at about the same rate.
Carlson’s “Law”

Special Challenges

- Lack of shared global language, risk assessment methodologies and standards in biosafety and biosecurity

- Challenge to traditional multilateral institutions, individual scientific organizations and national governments
Competing Issues

- Commercial Interests
  - Desire to measure up to global standards perceived to be in the strategic interest of private business and governments
- Basic health care – infectious disease
- Agriculture and food production

Global Approaches

- World Health Organization
- G-8 and Global Partnership
- National Academies of Science
- Global networks of life scientists
A Global Issue Network

- Networks can define norms for governments, business, and multilateral institutions”
- “Global issue networks can transcend the limits imposed by contemporary territorial and hierarchical institutions that were never constructed to address these inherently global changes”

Jean-Francois Rischard, Vice-President, World Bank

International Council for the Life Sciences

- Created in December 2005 to help enhance biological safety and security through international standards and the sharing of best practices
- Private organization
- Product of over three years of engagement of the global life science community
ICLS Mission

The mission of the Council is to help ensure global public health, safety and security by safeguarding the opportunities offered by advances in the life sciences and their application through the promotion of best practices, standards, and codes of conduct.

Senior Advisory Panel

- **Abdallah Daar**
  University of Toronto (Canada)
- **Robert Erwin**
  Large Scale Biology Corporation
- **Paul Fischer**
  GenVec
- **Jerome Gervais**
  Formerly of The Vaccine Fund (France)
- **William Haseltine**
  Haseltine Associates
- **Erling Myhre**
  Land University Hospital (Sweden)
- **Anwar Nasim**
  National Biotechnology Commission (Pakistan)
- **Mikhail Paltsev**
  Moscow Medical Academy and TEMPO
- **Julia Polak**
  Imperial College (UK)
- **Charles Penn**
  Syntaxin (UK)
- **George Poste**
  Arizona Bioscience Institute, Arizona State University
- **Usk Ryan**
  AVANT Immunotherapeutics
- **Martin Sanders**
  CDC
- **Gurinder Shahi**
  Global BioBusiness Initiative USC (Singapore)
- **Mark Smolinski**
  Global Health and Security Initiative
- **Rainer Wessel**
  GANYMED Pharmaceuticals (Germany)
ICLS Charter & Membership Obligations

- National and International Laws and Regulations
- Personnel
- Information
- Safe and Secure Operation of Facilities
- Governance of Research

ICLS - Creating Partnerships

- Common global standards for Biosafety Levels 1, 2, 3 and 4
- Safety and security training standards and curricula for personnel from academia, private industry and government
- Global multi-disciplinary biological risk assessment
ICLS Priority Action Areas

- International Biosecurity and Biosafety System
- Risk Assessment – common approach
- Briefings for policy officials

2006 Outreach

- OECD Conference on Biological Research Centres
- G-8 Seminar Moscow
- National Scientific Advisory Board on Biosecurity
- National Academies of Sciences
- Royal Society (UK)
- United Nations
- Dialogues Islam and the West
Risk Analysis

Risk analysis should answer three questions:

- What can go wrong?
- How likely is it to happen?
- What are the consequences?

Focus of Most Current Methodologies (3)
Stakeholder Cooperation

Successful **risk management** requires **cooperation** among all the **stakeholders**

Global Objectives

- International advisory groups on:
  - Training standards and curricula
  - Risk assessment methodologies
  - International Biosafety/biosecurity best practices and standards

- Membership:
  - Multi-disciplinary
  - Geographically representative
2007

- Develop the ICLS International Biosafety and Biosecurity System
  - Russia
  - Middle East and the Gulf
  - South Asia
  - East Asia
- Develop Biological Risk Analysis Methodology

Regional Meeting

- Planned to be in the Gulf in late 2007
- To include primarily representatives from countries in the Middle East, Gulf and South Asia
- Experts from other regions may also be invited
- Participants may be scientific and policy experts from academia, governments and the private sector
Regional Visit

- ICLS Director and Assistant Director to visit the region in January 2007
- Listening to views on the key issues
- Selecting a conference location
- Promoting participation from academia, governments and private industry
- Developing the network

ICLS Supporters

- NTI – Global Health and Security Initiative
- Alfred P. Sloan Foundation
- Foreign Affairs Canada
- Robert and Ardis James Foundation
- Private Individuals
ICLS Supporters (2)

- Avant Immunotherapeutics (US)
- Ganymed Pharmaceuticals (Germany)
- Haseltine Associates (US)
- Higher Education Commission (Pakistan)
- Syntaxin (UK)
- Toronto University (Canada)
- Virginia Technical University (US)

ICLS Supporters (3)

- Asia BioBusiness (Singapore)
- Imperial College (UK)
- Health Protection Agency (UK)
- I.M. Sechenov Moscow Medical Academy (Russia)
- Confederation of Indian Industry (India)
- National Biotechnology Commission (Pakistan)
- International Science and Technology Center
- World Health Organization
ICLS Contact Information

International Council for the Life Sciences
1747 Pennsylvania Avenue, Suite 700
Washington, DC 20006
Tel: +1 (202) 659-8058
Fax: +1 (202) 296-1134
taylor@iclscharter.org
runyon@iclscharter.org
lehman@iclscharter.org
www.iclscharter.org

Risk Analysis

Threat Scenarios → System at risk → Consequence Assessment → Risk value

Decision Alternatives
- emergency response
- consequence management
- prioritization
- policy / regulation

Risk perception and communication
! Don’t worry! Prepare to die!

Risk Management
Infectious Disease Risk Matrix (illustrative) (4)